---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-095073"
form_type: "8-K"
ticker: "ANNX"
cik: "0001528115"
company_name: "Annexon, Inc."
filed_at: "2024-08-12T23:59:59+00:00"
generated_at: "2026-05-31T10:01:40.423020+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Annexon Q2 2024 net loss narrowed to $29.6M; cash $368.7M, runway into H2 2026

## Summary
- Net loss of $29.6M ($0.23/shr) vs. $35.2M ($0.47/shr) in Q2 2023.
- Cash, equivalents and short-term investments $368.7M as of June 30, 2024; runway into H2 2026.
- ANX005 (GBS) Phase 3 met endpoints; RWE topline data expected year-end 2024; BLA filing H1 2025.
- ANX007 (GA) Phase 3 ARCHER II trial dosing initiated; topline data expected H2 2026.
- ANX1502 oral C1s inhibitor bridging study to tablet completed; POC data in CAD expected Q4 2024.

## SEC filing metadata
- accession: 0000950170-24-095073
- form_type: 8-K
- ticker: ANNX
- cik: 0001528115
- company_name: Annexon, Inc.
- filed_at: 2024-08-12T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1528115/000095017024095073/0000950170-24-095073-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1528115/000095017024095073/annx-20240812.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-095073
- JSON: https://secwatch.observer/filing/0000950170-24-095073.json
- Plain text: https://secwatch.observer/filing/0000950170-24-095073.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.